Brief: US FDA - Approves Isembyld For Spinal Muscular Atrophy In Patients Aged 2 Years And Older
11/09/2026 22:31
BRIEF-US FDA - Approves Isembyld For Spinal Muscular Atrophy In Patients Aged 2 Years And Older Sept 11 (Reuters) - Scholar Rock Holding Corporation SRRK.O:
US FDA - APPROVES ISEMBYLD FOR SPINAL MUSCULAR ATROPHY IN PATIENTS AGED 2 YEARS AND OLDER
Further company coverage: SRRK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scholar Rock Holding
See all newsBrief: Scholar Rock Reports New Employee Inducement Grants
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (Maa) To European Medicines Agency (EMA) For Treatment Of Children And Adults With Spinal Muscular Atrophy (SMA)
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up